After years of decline, malaria is on the rise.
In 2020, the estimated number of cases worldwide exceeded 240 million, and 627,000 people died, the majority of them children under the age of 5.
This is 69,000 more deaths than in 2019, two-thirds of which would be directly linked to the impact of the Covid pandemic, estimates the World Health Organization (WHO).
In this dark context, a recent publication of the
New England Journal of Medicine
(NEJM)
brings a glimmer of hope.
An international team presents the data of a phase 1 clinical trial evaluating a new generation of monoclonal antibodies whose single injection could confer
protection for six months against
Plasmodium falciparum,
the main parasite responsible for malaria.
The antibodies, called L9LS, evaluated in this clinical trial are directed against the CSP-1 protein present on the sporozoite form of
P. falciparum
.
“
This stage of development is that of the parasite when…
This article is for subscribers only.
You have 83% left to discover.
Pushing back the limits of science is also freedom.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login